



## **SurModics to Webcast Fiscal 2005 Third Quarter Earnings Conference Call July 20; Webcast is Live at 4:00 p.m. (CT)**

July 13, 2005

EDEN PRAIRIE, Minn., Jul 13, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2005 third quarter conference call on Wednesday, July 20, at 4:00 p.m. CT. The company will issue an earnings news release after the market closes that afternoon.

Bruce Barclay, President and Chief Executive Officer and Phil Ankeny, Chief Financial Officer and Vice President, Business Development, will recap the third quarter financial results and accomplishments. To access the webcast, go to the investor relations portion of the company's web site, [www.surmodics.com](http://www.surmodics.com), on the day of the conference call and click on the Webcast icon. If you do not have access to the Internet and want to listen to the audio, dial 800-257-7063.

An audio replay will be available beginning at 6:00 p.m. CT on Wednesday, July 20, until 6:00 p.m. CT on Wednesday, July 27 and can be accessed by dialing 800-405-2236 and entering conference call ID 11034737. In addition, the conference call audio will be archived on the company's web site following the call.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies, in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. A significant portion of SurModics' revenue is generated by royalties from the sale of commercial products resulting from its corporate relationships. Recent collaborative efforts include the implementation of the SurModics' Bravo(TM) drug delivery polymer matrix as a key component in the first-to-market drug-eluting coronary stent. SurModics is headquartered in Minneapolis, MN and more information about the company can be found at [www.surmodics.com](http://www.surmodics.com). The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.

SOURCE: SurModics, Inc.

SurModics, Inc.  
Phil Ankeny, 952-829-2700